 Connection
Charles Edelstein to Polycystic Kidney Diseases
This is a "connection" page, showing publications Charles Edelstein has written about Polycystic Kidney Diseases.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
6.458 |
|
|
|
-
Atwood DJ, He Z, Miyazaki M, Hopp K, Jani A, Furgeson SB, Faubel S, Edelstein CL. mTOR promotes the formation and growth of tertiary lymphoid tissues in the kidney. Front Immunol. 2025; 16:1527817.
Score: 0.846
-
Chaudhary A, He Z, Atwood DJ, Miyazaki M, Oto OA, Davidoff A, Edelstein CL. Raising serum uric acid with a uricase inhibitor worsens PKD in rat and mouse models. Am J Physiol Renal Physiol. 2024 06 01; 326(6):F1004-F1015.
Score: 0.784
-
Oto OA, Atwood DJ, Chaudhary A, He Z, Li AS, Wempe MF, Edelstein CL. Metformin does not slow cyst growth in the PCK rat model of polycystic kidney disease. Physiol Rep. 2023 09; 11(17):e15776.
Score: 0.751
-
Nowak KL, Edelstein CL. Apoptosis and autophagy in polycystic kidney disease (PKD). Cell Signal. 2020 04; 68:109518.
Score: 0.581
-
Holditch SJ, Brown CN, Atwood DJ, Pokhrel D, Brown SE, Lombardi AM, Nguyen KN, Hill RC, Lanaspa M, Hopp K, Weiser-Evans MCM, Edelstein CL. The consequences of increased 4E-BP1 in polycystic kidney disease. Hum Mol Genet. 2019 12 15; 28(24):4132-4147.
Score: 0.580
-
Ravichandran K, Zafar I, Ozkok A, Edelstein CL. An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease. Nephrol Dial Transplant. 2015 Jan; 30(1):45-53.
Score: 0.404
-
Ravichandran K, Zafar I, He Z, Doctor RB, Moldovan R, Mullick AE, Edelstein CL. An mTOR anti-sense oligonucleotide decreases polycystic kidney disease in mice with a targeted mutation in Pkd2. Hum Mol Genet. 2014 Sep 15; 23(18):4919-31.
Score: 0.393
-
Ravichandran K, Edelstein CL. Polycystic kidney disease: a case of suppressed autophagy? Semin Nephrol. 2014 Jan; 34(1):27-33.
Score: 0.381
-
Klawitter J, Zafar I, Klawitter J, Pennington AT, Klepacki J, Gitomer BY, Schrier RW, Christians U, Edelstein CL. Effects of lovastatin treatment on the metabolic distributions in the Han:SPRD rat model of polycystic kidney disease. BMC Nephrol. 2013 Jul 31; 14:165.
Score: 0.373
-
Belibi F, Zafar I, Ravichandran K, Segvic AB, Jani A, Ljubanovic DG, Edelstein CL. Hypoxia-inducible factor-1a (HIF-1a) and autophagy in polycystic kidney disease (PKD). Am J Physiol Renal Physiol. 2011 May; 300(5):F1235-43.
Score: 0.313
-
Zafar I, Belibi FA, He Z, Edelstein CL. Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD). Nephrol Dial Transplant. 2009 Aug; 24(8):2349-53.
Score: 0.276
-
Tao Y, Zafar I, Kim J, Schrier RW, Edelstein CL. Caspase-3 gene deletion prolongs survival in polycystic kidney disease. J Am Soc Nephrol. 2008 Apr; 19(4):749-55.
Score: 0.255
-
Tao Y, Kim J, Yin Y, Zafar I, Falk S, He Z, Faubel S, Schrier RW, Edelstein CL. VEGF receptor inhibition slows the progression of polycystic kidney disease. Kidney Int. 2007 Dec; 72(11):1358-66.
Score: 0.248
-
Edelstein CL. What is the role of tubular epithelial cell apoptosis in polycystic kidney disease (PKD)? Cell Cycle. 2005 Nov; 4(11):1550-4.
Score: 0.219
-
Tao Y, Kim J, Faubel S, Wu JC, Falk SA, Schrier RW, Edelstein CL. Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease. Proc Natl Acad Sci U S A. 2005 May 10; 102(19):6954-9.
Score: 0.053
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|